ArticleCancer management and research2017

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.

Nishant Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.